艰难梭菌嵌合毒素受体结合域疫苗在主动与被动攻击模型中诱导针对不同菌株的保护
研究构建了艰难梭菌三价(CDTb/TcdB(003)/TcdA)和四价(CDTb/TcdB(003)/TcdA/TcdB(027))毒素融合蛋白疫苗,小鼠或仓鼠主动免疫后产生针对各毒素的中和抗体,四价疫苗免疫的仓鼠对历史株630和流行株NAP1攻击获得广泛保护;用融合蛋白免疫转基因牛制备的全人源多克隆抗毒素IgG在被动转移中使小鼠免受致死性毒素攻击,并使仓鼠在历史株或流行株攻击时获得完全保护。
要点
- 四价毒素融合蛋白疫苗免疫仓鼠对历史株630和流行株NAP1的孢子攻击获得广泛保护。
- 主动免疫小鼠或仓鼠后产生针对各毒素的毒素中和抗体。
- 全人源多克隆抗毒素IgG被动转移使小鼠免受致死性毒素攻击,仓鼠获完全保护。
核心结论
- 嵌合融合蛋白是生产多价抗毒素疫苗和治疗性多克隆抗体用于预防和治疗艰难梭菌感染(CDI)的有吸引力的方法。
研究设计与样本
- 研究构建了基于TcdA、TcdB(003)、TcdB(027)和CDT受体结合域(RBD)的三价毒素(T-toxin,CDTb/TcdB(003)/TcdA)和四价毒素(Q-toxin,CDTb/TcdB(003)/TcdA/TcdB(027))融合蛋白疫苗。
- 在小鼠或仓鼠中进行主动免疫,并通过免疫转基因牛制备全人源多克隆抗毒素IgG,开展被动转移研究。
主要发现
- 用T-toxin或Q-toxin融合蛋白疫苗主动免疫小鼠或仓鼠,产生了针对每种毒素的毒素中和抗体。
- 用Q-toxin疫苗免疫的仓鼠对历史株艰难梭菌630(毒素型0/核糖体型003)和流行株NAP1(毒素型III/核糖体型027)的孢子攻击获得广泛保护。
- 在被动转移研究中,小鼠免受致死性毒素攻击。
- 用人抗毒素IgG处理的仓鼠在受到历史株或流行株艰难梭菌攻击时获得完全保护。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clostridium difficile is the number one cause of nosocomial antibiotic-associated diarrhea in developed countries. Historically, pathogenesis was attributed two homologous glucosylating toxins, toxin-A (TcdA) and toxin-B (TcdB). Over the past decade, however, highly virulent epidemic strains of C. difficile (B1/NAP1/027) have emerged and are linked to an increase in morbidity and mortality. Increased virulence is attributed to multiple factors including: increased production of A- and B-toxins; production of binary toxin (CDT); and the emergence of more toxic TcdB variants (TcdB(027)). TcdB(027) is more cytotoxicity to cells; causes greater tissue damage and toxicity in animals; and is antigenically distinct from historical TcdB (TcdB(003)). Broadly protective vaccines and therapeutic antibody strategies, therefore, may target TcdA, TcdB variants and CDT. To facilitate the generation of multivalent toxin-based C. difficile vaccines and therapeutic antibodies, we have generated fusion proteins constructed from the receptor binding domains (RBD) of TcdA, TcdB(003), TcdB(027) and CDT. Herein, we describe the development of a trivalent toxin (T-toxin) vaccine (CDTb/TcdB(003)/TcdA) and quadravalent toxin (Q-toxin) vaccine (CDTb/TcB(003)/TcdA/TcdB(027)) fusion proteins that retain the protective toxin neutralizing epitopes. Active immunization of mice or hamsters with T-toxin or Q-toxin fusion protein vaccines elicited the generation of toxin neutralizing antibodies to each of the toxins. Hamsters immunized with the Q-toxin vaccine were broadly protected against spore challenge with historical C. difficile 630 (toxinotype 0/ribotype 003) and epidemic NAP1 (toxinotype III/ribotype 027) strains. Fully human polyclonal antitoxin IgG was produced by immunization of transgenic bovine with these fusion proteins. In passive transfer studies, mice were protected against lethal toxin challenge. Hamsters treated with human antitoxin IgG were completely protected when challenged with historical or epidemic strains of C. difficile. The use of chimeric fusion proteins is an attractive approach to producing multivalent antitoxin vaccines and therapeutic polyclonal antibodies for prevention and treatment of C. difficile infections (CDI).
引用
- Tian JH, Glenn G, Flyer D, et al. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models. Vaccine. 2017. PMID: 28669616. doi:10.1016/j.vaccine.2017.06.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。